Source:http://linkedlifedata.com/resource/pubmed/id/11335792
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
2001-5-3
|
| pubmed:abstractText |
The objective of this study was to define the minimally effective dose of cyclosporin A (CsA) that would result in a maximal increase of the systemic exposure to oral paclitaxel. Six evaluable patients participated in this randomized cross-over study in which they received at two occasions two doses of 90 mg/m(2) oral paclitaxel 7 h apart in combination with 10 or 5 mg/kg CsA. Dose reduction of CsA from 10 to 5 mg/kg resulted in a statistically significant decrease in the area under the plasma concentration-time curve (AUC) and time above the threshold concentrations of 0.1 microM (T>0.1 microM) of oral paclitaxel. The mean (+/-SD) AUC and T>0.1 microM values of oral paclitaxel with CsA 10 mg/kg were 4.29+/-0.88 microM x h and 12.0+/-2.1 h, respectively. With CsA 5 mg/kg these values were 2.75+/-0.63 microM x h and 7.0+/-2.1 h, respectively (p=0.028 for both parameters). In conclusion, dose reduction of CsA from 10 to 5 mg/kg resulted in a significant decrease in the AUC and T>0.1 microM values of oral paclitaxel. Because CsA 10 mg/kg resulted in similar paclitaxel AUC and T>0.1 microM values compared to CsA 15 mg/kg (data which we have published previously), the minimally effective dose of CsA is determined at 10 mg/kg.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
0959-4973
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
12
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
351-8
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:11335792-Adenocarcinoma,
pubmed-meshheading:11335792-Administration, Oral,
pubmed-meshheading:11335792-Adult,
pubmed-meshheading:11335792-Aged,
pubmed-meshheading:11335792-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11335792-Area Under Curve,
pubmed-meshheading:11335792-Breast Neoplasms,
pubmed-meshheading:11335792-Carcinoma, Small Cell,
pubmed-meshheading:11335792-Cyclosporine,
pubmed-meshheading:11335792-Dose-Response Relationship, Drug,
pubmed-meshheading:11335792-Drug Administration Schedule,
pubmed-meshheading:11335792-Female,
pubmed-meshheading:11335792-Gastrointestinal Diseases,
pubmed-meshheading:11335792-Hematologic Diseases,
pubmed-meshheading:11335792-Humans,
pubmed-meshheading:11335792-Infusions, Intravenous,
pubmed-meshheading:11335792-Lung Neoplasms,
pubmed-meshheading:11335792-Male,
pubmed-meshheading:11335792-Middle Aged,
pubmed-meshheading:11335792-Neoplasms,
pubmed-meshheading:11335792-Paclitaxel,
pubmed-meshheading:11335792-Premedication,
pubmed-meshheading:11335792-Stomach Neoplasms,
pubmed-meshheading:11335792-Uterine Cervical Neoplasms,
pubmed-meshheading:11335792-Uterine Neoplasms
|
| pubmed:year |
2001
|
| pubmed:articleTitle |
The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel.
|
| pubmed:affiliation |
Department of Medical Oncology, Netherlands Cancer Institute/Slotervaart Hospital, Louwesweg 6, 1066 EC Amsterdam, The Netherlands. apmmg@slz.nl
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|